The Bio Report
by Levine Media Group
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 28 chart positions in 28 markets.
By chart position
- 🇬🇧GB · Life Sciences#1275K to 30K
- 🇨🇦CA · Life Sciences#1595K to 30K
- 🇺🇸US · Life Sciences#1685K to 30K
- 🇩🇪DE · Life Sciences#1845K to 30K
- 🇦🇺AU · Life Sciences#1985K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
63K to 228K🎙 Daily cadence·611 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
210K to 761K🇰🇷13%🇹🇼13%🇵🇭13%+25 more - Active Followers
Loyal subscribers who consistently listen
63K to 228K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 22 epsHosts
Not detected.
Recent guests
Recent episodes
Addressing a Data Problem to Enable AI-Drug Discovery
Jul 15, 2026
41m 05s
Turning Multi Specific Antibody Design into an Engineering Discipline with AI
Jul 8, 2026
29m 42s
Addressing the Treatment Gap in Ischemic Stroke
Jul 1, 2026
30m 18s
A Pipeline in a Product that Reimagines Control of Inflammation
Jun 24, 2026
24m 04s
Building a Genetics Engine to Crack the Target Bottleneck
Jun 17, 2026
52m 43s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/15/26 | AI in drug discoverylab-generated data+3 | David Younger | A-Alpha Bio | — | AIdrug discovery+5 | — | 41m 05s | ||
| 7/8/26 | multi-specific antibodiesT-cell engagers+3 | Angus Sinclair | LabGenius | — | multi-specific antibodiesT-cell engagers+5 | — | 29m 42s | ||
| 7/1/26 | ischemic stroketreatment gap+3 | Julia OwensShahid Nimjee | Basking Biosciencesvon Willebrand factor | — | ischemic strokethrombolytic+5 | — | 30m 18s | ||
| 6/24/26 | inflammationhealth+4 | Susan Levinson | recombinant human plasma gelsolinBioAegis Therapeutics | acute respiratory distress syndrome | plasma gelsolininflammation+5 | — | 24m 04s | ||
| 6/17/26 | drug discoverygenetics+3 | Aris Baras | RegeneronRegeneron Genetics Center | — | drug discoverygenetics+5 | — | 52m 43s | ||
| 6/10/26 | epigeneticscancer treatment+3 | Terry Connolly | first‑in‑class medicinesexperimental therapies+2 | — | epigeneticscancer+5 | — | 28m 10s | ||
| 6/3/26 | antibody drug designmachine learning+3 | Angela Hwang | Metaphore Biotechnologies | — | antibodiesagonists+5 | — | 37m 31s | ||
| 5/27/26 | cellular stress biologydrug development+3 | Yerem Yeghiazarians | Soley TherapeuticsSoley | — | cellular stressAI platform+3 | — | 30m 10s | ||
| 5/20/26 | drug innovationpharmacology+3 | Eric Elenko | PureTech Health | — | abandoned drugstherapeutics+3 | — | 30m 38s | ||
| 5/13/26 | cancer therapyRNA technology+3 | Robert Schickel | NuagoLevine Media Group | liverovarian+1 | cancersurvival genes+3 | — | 45m 50s | ||
| 5/6/26 | goutarthritis+3 | James Mackay | Crystalys TherapeuticsLevine Media Group+1 | — | gouturate levels+5 | — | 36m 33s | ||
| 4/29/26 | cell therapycytokine storms+4 | Silviu Itescu | RyoncilMesoblast+1 | — | mesenchymal stromal cellsRyoncil+5 | — | 28m 29s | ||
| 4/22/26 | multiple sclerosisneurodegeneration+4 | Daniel Vitt | Immunic TherapeuticsLevine Media Group+1 | — | multiple sclerosisImmunic Therapeutics+5 | — | 29m 18s | ||
| 4/15/26 | immunologyinflammatory bowel disease+3 | Marc de Garidel | AbivaxHIV candidate | IBD | inflammatory bowel diseaseimmunosuppressive therapies+3 | — | 35m 47s | ||
| 4/8/26 | cancerimmune system+3 | Marina Udier | NouscomLynch syndrome | — | cancerLynch syndrome+5 | — | 39m 29s | ||
| 4/1/26 | Alzheimer's diseasepsychosis+3 | Elizabeth Thompson | Acadia PharmaceuticalsAlzheimer’s disease | — | Alzheimer'spsychosis+4 | — | 22m 09s | ||
| 3/25/26 | class action lawsuitpharmaceutical industry+4 | Harrison James | ActosWisner Baum+3 | — | RICOclass action+7 | — | 42m 56s | ||
| 3/18/26 | pancreatic cancertargeted cancer therapy+3 | Ben Zeskind | ImmuneeringLevine Media Group+1 | — | pancreatic cancerMEK inhibitor+3 | — | 38m 19s | ||
| 3/11/26 | autoimmune diseasesgene editing+3 | Richard Freed | RheumaGenLevine Media Group+1 | rheumatoid arthritis | autoimmunityHLA genes+5 | — | 37m 10s | ||
| 3/4/26 | biopharmaceutical innovationdrug development+3 | Fangning Zhang | McKinsey & Company | ChinaJapan+1 | biopharmainnovation+6 | — | 40m 20s | ||
| 2/25/26 | cancer treatmentprecision medicine+3 | Aaron Viny | Columbia UniversityColumbia University Vagelos College of Physician and Surgeons | — | leukemiachemotherapy+4 | — | 52m 47s | ||
| 2/18/26 | oncologypharmaceuticals+3 | Amy Burroughs | allosteric BCR-ABL inhibitorTerns Pharmaceuticals+1 | multibillion-dollar market | obesitycancer+3 | — | 22m 53s |
Showing 22 of 22
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for The Bio Report
Peaked at #9 in TW, top 10 in 2 of 30 tracked markets, currently #9 in TW.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| TW | — | #9 | #9 | — |
| PH | — | #10 | #10 | — |
| CO | — | #21 | #21 | — |
| HU | — | #26 | #26 | — |
| South Korea | — | #26 | #26 | — |
| SG | — | #32 | #32 | — |
| PL | — | #50 | #50 | — |
| Japan | — | #57 | #57 | — |
| IL | — | #64 | #64 | — |
| Spain | — | #66 | #66 | — |
| Italy | — | #71 | #71 | — |
| TW | — | #77 | #77 | — |
| AE | — | #88 | #88 | — |
| PT | — | #94 | #94 | — |
| PH | — | #95 | #95 | — |
| Sweden | — | #100 | #100 | — |
| HK | — | #101 | #101 | — |
| CH | — | #102 | #102 | — |
| Ireland | — | #103 | #103 | — |
| Finland | — | #107 | #107 | — |
Chart Positions
30 placements across 28 markets.
Chart Positions
30 placements across 28 markets.